Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 030 • 2020 Pediatric Rheumatology Symposium
The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis
Shiri Rubin ¹, Rotem Tal ², Ori Goldberg ³, Yoel Levinsky ⁴, Zohar Habot-Wilner ⁵, Orly Ohana ⁶, Yulia Gendler ⁷, Liora Harel ⁸ and Gil Amarilyo⁹, ¹Schneider Children's hospital of Israel, Tel Aviv university, Petach Tikva, Israel, ²schneider medical center, Ramat Gan, Israel, ³Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁴Schneider Children's Medical Cnetr of Israel, Tel Aviv University, Petach Tikva, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv Univrsity, Tel Aviv, Israel, ⁶Schneider Children's Medical Cener of Israel, Petach Tikva, Israel, ⁷Schneider Children's Medical Center of Israel, Tel Aviv Univesity, Petach Tikva, Israel, ⁸Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ⁹Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Intra-articular corticosteroids joint injection (IAJI) with Triamcinolone hexacetonide (TH) or triamcinolone acetonide…
Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Mei-Sing Ong¹, Gordon Schiff ² and Marc Natter ³ for the CARRA investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Harvard Medical School, Boston, ³Boston Children's Hospital, Boston
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…
Abstract Number: 179 • 2020 Pediatric Rheumatology Symposium
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Esi Morgan ², Sheetal Vora ³, Mileka Gilbert ⁴, Cagri Yildirim-Toruner ⁵, Nancy Griffin ⁶, Kerry Ferraro ⁷, Stephanie Loos ⁶, Tingting Qiu ⁶, Anne Paul ⁸, Jon Burnham ⁹, Erik Meyer ⁷, Michelle Batthish ¹⁰, Beth Gottlieb ¹¹, Danielle Bullock ¹², Melissa Hazen ¹³, Ronald Laxer ¹⁴, Tzielan Lee ¹⁵, Melissa Mannion ¹⁶, Judyann Olson ¹⁷, Michael Shishov ¹⁸, Richard Vehe ¹⁹, Jennifer Weiss ²⁰ and C. April Bingham ²¹, ¹Children's Mercy Kansas City, Overland Park, ²Cincinnati Children's Hospital, Cincinnati, ³Atrium Health Levine Children's Hospital, Charlotte, ⁴Medical University of South Carolina, Charleston, South Carolina, ⁵Nationwide Children's Hospital, Columbus, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Cincinnati Children's Hospital Medical Centre, Cincinnati, ⁹Children's Hospital of Philadelphia, Philadelphia, ¹⁰McMaster University, Hamilton, Canada, ¹¹Cohen Children's Medical Center, Lake Success, ¹²University of Minnesota, Minneapolis, ¹³Boston, ¹⁴The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁵Stanford Children's, Palo Alto, ¹⁶University of Alabama at Birmingham, Birmingham, ¹⁷Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ¹⁸Phoenix Children's Hospital, Phoenix, ¹⁹University of Minnesota, Roseville, ²⁰Hackensack University Medical Center, Hackensack, ²¹Penn State Children's Hospital, Allentown
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient…
Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Alexandra Munroe¹, Adam Huber ², Bianca Lang ³, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Dalhousie University - Halifax, Halifax, Canada, ⁴IWK Health Centre, Halifax, Canada
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 181 • 2020 Pediatric Rheumatology Symposium
Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) can be difficult and lead to undesirable outcomes in terms of socio-professional…
Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Sara Concha¹, Pamela Morales ², Eduardo Talesnik ¹ and Arturo Borzutzky ¹, ¹Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, ²Department of Pediatric, Clinica Las Condes, Santiago, Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
Abstract Number: 115 • 2020 Pediatric Rheumatology Symposium
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
Kimberly Lewis¹, Nico Osier ², Patricia Carter ³, Christina Nguyen ⁴, Ruy Carrasco ⁵, Shelby Brooks ², Alexandra Garcia ⁶ and Stefano Tiziani ⁵, ¹The University of Texas at Austin, Austin, Texas, ²The University of Texas at Austin, Austin, ³University of Alabama, Tuscalossa, ⁴Ascension Seton Nursing Research, Austin, ⁵The University of Texas at Austin, Dell Medical School, Austin, ⁶The University of Texas at Austin, Dell Medical School, School of Nursing, Austin
Background/Purpose: The purpose of this study is to define the relationships between pain and carbohydrate metabolism in teens with active juvenile idiopathic arthritis (JIA), teens…
Abstract Number: 182 • 2020 Pediatric Rheumatology Symposium
Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) may be a difficult period with challenges in socio-professional integration and in…
Abstract Number: 047 • 2020 Pediatric Rheumatology Symposium
Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts
Yongdong Zhao¹, Timothy Beukelman ², Yukiko Kimura ³, Mara Becker ⁴, Sarah Ringold ⁵, Anne Dennos ⁶ and Laura Schanberg ⁷ for the CARRA investigators, ¹University of Washington, Seattle, ²University of Alabama at Birmingham, Birmingham, ³Hackensack Meridian School of Medicine, Hackensack, ⁴Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ⁵Seattle Children's, Seattle, ⁶Duke University, Durham, ⁷Duke University Hospital, DURHAM
Background/Purpose: In July 2015, the CARRA Registry was re-established as a multi-center observational study that collects essential data from patients with childhood-onset rheumatic diseases. The…
Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ⁷, Marinka Twilt ⁸ and Timothy Beukelman ⁹, ¹Florida, Gainesville, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵University of Alberta, Edmonton, Canada, ⁶Amgen, Long Beach, ⁷Amgen, Inc, San Francisco, ⁸Alberta Children's Hospital, Calgary, Canada, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 184 • 2020 Pediatric Rheumatology Symposium
A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents
Ashley Cooper¹, Elaine Flanagan ², Tova Ronis ³, Baruch Goldberg ⁴, Ashley Sherman ¹, Chelsey Smith ⁵ and Gary Holland ⁶ for the CARRA investigators, ¹Children's Mercy Kansas City, Kansas City, ²Emory University, Atlanta, ³Children's National Hospital, Washington, ⁴UT Physicians, Houston, ⁵Children's Mercy Kansas City, Holden, ⁶
Background/Purpose: Chronic anterior uveitis is a sight-threatening complication of juvenile idiopathic arthritis (JIA). Prompt treatment to prevent complications requires regular screening and detection of uveitis…
Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 779 • 2019 ACR/ARP Annual Meeting
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Kaiyu Jiang ¹, Yungki Park ¹, Tarbell Evan ¹, Tao Liu ² and James N. Jarvis³, ¹University at Buffalo Jacobs School of Medicine, Buffalo, NY, ²Roswell Park Cancer Instiyute, Buffalo, NY, ³University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY
Background/Purpose: IL2RA has been identified as a JIA-associated risk locus using both candidate gene and genetic fine mapping approaches. However, numerous gene expression studies comparing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].